ACADIA to Host Conference Call and Webcast on
Wednesday,
August 5, 2009, at 5:00 p.m. Eastern Time
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the second quarter ended June 30, 2009 on Wednesday, August 5, 2009,
after the U.S. financial markets close. ACADIA's management will host a
conference call and webcast on Wednesday, August 5, 2009, at 5:00 p.m.
Eastern Time to discuss ACADIA’s financial results and development
programs.
The conference call may be accessed by dialing 866-831-6234 for
participants in the U.S. or Canada and 617-213-8854 for international
callers (reference passcode 31522932). A telephone replay of the
conference call may be accessed through August 19, 2009 by dialing
888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for
international callers (reference passcode 97036682). The conference call
also will be webcast live on ACADIA’s website, www.acadia-pharm.com,
under the investors section and will be archived there until August 19,
2009.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for
central nervous system disorders. ACADIA is currently developing a
portfolio consisting of its five most advanced product candidates
including pimavanserin, which is in Phase III development for
Parkinson’s disease psychosis in collaboration with Biovail. In addition
to pimavanserin, ACADIA has a product candidate in Phase II for chronic
pain and a product candidate in Phase I for glaucoma, both in
collaboration with Allergan, as well as two programs in IND-track
development. All of the product candidates in ACADIA’s pipeline emanate
from discoveries made using its proprietary drug discovery platform.
ACADIA maintains a website at www.acadia-pharm.com
to which ACADIA regularly posts copies of its press releases as well as
additional information and through which interested parties can
subscribe to receive email alerts.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director,
Investor Relations
Thomas H. Aasen, Vice President and Chief
Financial Officer
(858) 558-2871
